Serum High Lipoprotein(a) Levels in Patients with Type 2 Diabetes May Be an Independent Risk Factor for Hypertension

Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v2i2.347

Lingfen Zeng, Jieming Sun, Ming Cui

Department of Internal Medicine, Third People's Hospital, Baiyun District, Guangzhou 510000, Guangdong, China

Abstract

Objective — To investigate whether serum lipoprotein(a) [Lp(a)] is an independent risk factor for abnormal blood pressure in patients with type 2 diabetes mellitus. Method — Analyzed data collected from diabetes patients and epidemiological survey from January 1,2020 to May 01,2021, with hypertension as a dependent variable, metabolic index such as glycosylated hemoglobin, serum total cholesterol, serum triglyceride and Lp(a) were independent variables, established logistic regression equation, analyze the influence of their variables on dependent variables. Results — The OR value of Lp(a) is 1.020, 95% confidence intervals (1.006, 1.035), p 0.006; The OR value of age is 1.073, 95% confidence interval (1.028, 1.119); and OR of the remaining parameters were tested no statistically different, p>0.05. Conclusions — The abnormal elevated Lp(a) level in the serum of type 2 diabetic patients may be related to the occurrence of hypertension. For patients with high Lp(a), Monitoring blood pressure may help to better detect and diagnose hypertension. At the same time, it is suggested that reducing serum Lp(a) level may reduce the risk of hypertension.

Keywords

diabetes, lipoprotein(a), hypertension

Funding

Medical and Health Technology Plan Project of Baiyun District, Guangzhou (2020-YL-037)

Full Text

PDF - Viewed/Downloaded: 24 Times

References

[1]Zhang YQ, Li Y, Dong YG, et al. A nationwide assessment of blood pressure control and the associated factors in Chinese type 2 diabetes mellitus patients. J Clin Hypertens (Greenwich), 2019; 21(11): 1654-1663.
[2]Mancusi C, Izzo R, di Gioia G, et al. Insulin Resistance the Hinge Between Hypertension and Type 2 Diabetes. High Blood Press Cardiovasc Prev. 2020; 27(6): 515-526.
[3]Paré G, Çaku A, McQueen M, el al. Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups. Circulation. 2019; 139(12): 1472-1482.
[4]Cho JH, Lee DY, Lee ES, el al. Increased risk of coronary artery calcification progression in subjects with high baseline Lp(a) levels: The Kangbuk Samsung Health Study. Int J Cardiol. 2016; 222: 233-237.
[5]Langsted A, Nordestgaard BG, Kamstrup PR. Elevated Lipoprotein(a) and Risk of Ischemic Stroke. J Am Coll Cardiol. 2019; 74(1): 54-66.
[6]Paige E, Masconi KL, Tsimikas S, et al. Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature. Cardiovasc Diabetol. 2017; 16(1): 38.
[7]Rhee EJ, Cho JH, Lee DY, et al. Insulin resistance contributes more to the increased risk for diabetes development in subjects with low lipoprotein(a) level than insulin secretion. PLoS One. 2017; 12(5): e0177500.
[8]Boronat M, Saavedra P, Pérez-Martín N, et al. High levels of lipoprotein(a) are associated with a lower prevalence of diabetes with advancing age: results of a cross-sectional epidemiological survey in Gran Canaria, Spain. Cardiovasc Diabetol. 2012; 11: 81.
[9]Utermann G. The mysteries of lipoprotein(a). Science. 1989; 246(4932): 904-910.
[10]Kraft HG, Menzel HJ, Hoppichler F, et al. Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. J Clin Invest. 1989; 83(1): 137-142.
[11]Boerwinkle E, Leffert CC, Lin J, et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992; 90(1): 52-60.
[12]Miles LA, Plow EF. Lp(a): an interloper into the fibrinolytic system? Thromb Haemost. 1990; 63(3): 331-335.
[13]Brown MS, Goldstein JL. Plasma lipoproteins: teaching old dogmas new tricks. Nature. 1987; 330(6144): 113-114.
[14]Bergmark C, Dewan A, Orsoni A, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res. 2008; 49(10): 2230-2239.
[15]Noma A, Abe A, Maeda S, et al. Lp(a): an acute-phase reactant? Chem Phys Lipids. 1994; 67-68: 411-417.
[16]Mooser V, Berger MM, Tappy L, Cayeux C, Marcovina SM, Darioli R, Nicod P, Chioléro R. Major reduction in plasma Lp(a) levels during sepsis and burns. Arterioscler Thromb Vasc Biol. 2000; 20(4): 1137-1142.
[17]Ferretti G, Bacchetti T, Johnston TP, et al. Lipoprotein(a): A missing culprit in the management of athero-thrombosis? J Cell Physiol. 2018; 233(4): 2966-2981.
[18]Lacruz ME, Kluttig A, Hartwig S, et al. Prevalence and Incidence of Hypertension in the General Adult Population: Results of the CARLA-Cohort Study. Medicine. 2015; 94(22): e952.
[19]Stein EA, Raal F. Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease. Cardiovasc Drugs Ther. 2016; 30(1): 101-108.

Citing this article:

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License